New Zealand markets closed

ALX Oncology Holdings Inc. (ALXO)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
54.05+0.22 (+0.41%)
At close: 4:00PM EDT
54.05 0.00 (0.00%)
After hours: 04:01PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close53.83
Open53.83
Bid52.25 x 1200
Ask64.10 x 1100
Day's range52.61 - 54.42
52-week range38.09 - 117.45
Volume97,323
Avg. volume264,683
Market cap2.181B
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-1.62
Earnings date10 Nov 2021 - 15 Nov 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est98.38
  • GlobeNewswire

    ALX Oncology Announces First Patient Dosed in ASPEN-05, a Phase 1/2 Study of Evorpacept in Combination with Venetoclax and Azacitidine in Patients with Acute Myeloid Leukemia

    Second study of evorpacept in patients with myeloid malignanciesSOUTH SAN FRANCISCO, Calif., Oct. 21, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced the first patient has been dosed in the Phase 1/2 ASPEN-05 study evaluating the combination of evorpacept, a next-generation CD47 blocker, with venetoclax and azacitidine for the treatment of pa

  • GlobeNewswire

    ALX Oncology Strengthens Immuno-Oncology Pipeline with Acquisition of ScalmiBio

    Acquisition adds novel and proprietary SHIELD platform for conditional activation of antibodies in tumor microenvironment and proprietary cytotoxic payloads for antibody drug conjugatesExpands ALX Oncology’s pipeline of drug candidates based on expertise in protein engineering and oncology SOUTH SAN FRANCISCO, Calif., Oct. 07, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company, and ScalmiBio, Inc. (“ScalmiBio”) announced

  • GlobeNewswire

    ALX Oncology Announces Four Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting

    SOUTH SAN FRANCISCO, Calif., Oct. 01, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”), a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint mechanism, today announced that four abstracts have been accepted for presentation at the SITC 36th Annual Meeting in Washington D.C. from November 10 –14, 2021. The abstracts, which will be presented in a poster session, include new clinical data from ASPEN-01, the ongoing Phase 1b